The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Share News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Revenue and earnings rise at Immunodiagnostic Systems

Wed, 17th Jun 2020 12:08

(Sharecast News) - In-vitro diagnostics provider Immunodiagnostic Systems met its target of maintaining like-for-like revenue in its final results on Wednesday, with group revenue rising by 2% on a like-for-like basis to £39.3m, making for its second consecutive year of revenue growth.
The AIM-traded company said automated business revenue increased by 4% on a like-for-like basis for the year ended 31 March, driven by higher sales of speciality assays.

Revenue for autoimmune and infectious disease assays grew 74% like-for-like, while revenue from its automated distribution channels grew 30% like-for-like.

The firm said its manual business declined by 8% like-for-like, due to lower sales in direct European markets, while its technology business generated £4.6m of revenue, making for a like-for-like increase of 30%.

Total gross instrument sales and placements across Immunodiagnostic Systems' automated and technology business units reached 150, up from 127 year-on-year and the strongest performance since 2012.

Placements in its direct markets totalled 43, up from 37, with returns of 25, rising marginally from 24.

As a result, net placements in direct markets increased to 18 from 13 year-on-year.

Instrument sales to distributors increased to 50 from 47, and instrument sales to original equipment manufacturer customers in the technology business unit increased to 57 from 43.

Immunodiagnostic Systems said its gross margin improved to 44% from 43% due to cost efficiency efforts, which were partially offset by an adverse sales mix.

Adjusted EBITDA rose to £6.1m from £4.8m year-on-year.

At the end of the 2020 financial year, the company said it had a total of 141 CE-marked assays available for sale on its analysers - up from 135 - 22 of which were in-house developments, in line with the prior year.

"During the 2020 financial year we delivered a second consecutive year of like for like revenue growth, [and] we also increased the number of analysers sold or placed to 150, compared to 127," noted chief executive officer Jaap Stuut.

"Our results in the first quarter of the 2021 financial year will be significantly impacted by reduced laboratory testing volumes, however once the pandemic subsides, we believe we are in a strong position to continue our revenue growth.

"Additionally, we have an opportunity to commercialise our range of automated and manual SARS-CoV-2 (Covid-19) antibody testing kits, which we plan to launch during June."

At 1052 BST, shares in Immunodiagnostic Systems Holdings were up 4.29% at 286.6p.
More News
22 Jun 2016 06:59

Immunodiagnostic Systems Swings To Loss On Impairment Charges

Read more
15 Jun 2016 15:14

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
9 Jun 2016 09:38

WINNERS & LOSERS SUMMARY: Essentra Shares Crushed By Profit Warning

Read more
9 Jun 2016 07:53

Immunodiagnostic System Holdings Warns On Revenue After Royalty Hit

Read more
6 May 2016 12:12

Immunodiagnostic launches first product in fertility portfolio

(ShareCast News) - Specialty clinical laboratory diagnostic solutions company Immunodiagnostic Systems Holdings announced the launch of the IDS-iSYS 17-OH Progesterone assay in the European market - the first product released as part of its upcoming steroid hormones fertility portfolio. The AIM-trad

Read more
6 May 2016 09:38

Immunodiagnostic Systems Launches 17-OH Progesterone Assay In Europe

Read more
25 Apr 2016 09:44

Immunodiagnostic Systems warns of revenue decline

(ShareCast News) - Immunodiagnostic Systems confirmed sales will fall year-on-year as demand trends have not improved substantially since November, while significant asset write-downs could send it into the red. Total revenues are expected to fall 13.3% to roughly £39m for the year to 31 March, the

Read more
25 Apr 2016 09:38

WINNERS & LOSERS SUMMARY: St Ives Dives After Profit Warning

Read more
25 Apr 2016 06:57

Immunodiagnostic Systems Expects "Significant" Asset Write Down

Read more
15 Apr 2016 15:02

Earnings, Trading Statements Calendar - Week Ahead

Read more
8 Jan 2016 08:00

Immunodiagnostic Says UK Jobs Potentially Cut With Manufacturing Move

Read more
18 Dec 2015 11:21

Immunodiagnostic Launches Salivary Cortisol Test In European Market

Read more
24 Nov 2015 11:50

Immunodiagnostic Warns Revenue To Fall As Conditions Still Challenging

Read more
17 Nov 2015 16:19

Earnings, Trading Statements Calendar - Week Ahead

Read more
22 Oct 2015 13:31

Immunodiagnostic Systems Appoints Paul Martin Chief Financial Officer

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.